Tpl2 kinase impacts Tumor growth and metastasis of clear cell renal cell carcinoma

Molecular Cancer Research

Volumn 11, Issue 11, 2013, Pages 1375-1386

  Lee, Hye Won ^a   Joo, Kyeung Min ^a   Lim, Joung Eun ^a   Cho, Hyun Jung ^a   Cho, Hee Jin ^a   Park, Min Chul ^b   Seo, Ho Jun ^a   Seo, Seong Il ^a   Lee, Jung Il ^a   Kim, Sunghoon ^b   Jeong, Byong Chang ^a   Nam, Do Hyun ^a  

^a Sungkyunkwan University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PROTEIN KINASE; SHORT HAIRPIN RNA; STROMAL CELL DERIVED FACTOR 1; TUMOR PROGRESSION LOCUS 2; UNCLASSIFIED DRUG;

ANOIKIS; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CLONOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; GENOME; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LUNG METASTASIS; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR GROWTH; UPREGULATION; XENOGRAFT;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MAP KINASE KINASE KINASES; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888241831     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0101-T     Document Type: Article

References (48)

1. Dosemeci M, Cocco P, Chow WH. Gender differences in risk of renal cell carcinoma and occupational exposures to chlorinated aliphatic hydrocarbons. Am J Ind Med 1999;36:54-9.
2. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331-4.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cellcarcinoma. N Engl JMed 1996;335:865-75.
4. Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007;99:296-300.
5. Tsui KH, Shvarts O, Smith RB, Figlin RA, de Kernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163:1090-5.
6. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-6.
7. Meloni-Ehrig AM. Renal cancer: cytogenetic and molecular genetic aspects. Am J Med Genet 2002;115:164-72.
8. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604-14.
9. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:2763-71.
10. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009;11:94-101.
11. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol 2001;21:5958-69.
12. Vougioukalaki M, Kanellis DC, Gkouskou K, Eliopoulos AG. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett 2011;304:80-9.
13. Sourvinos G, Tsatsanis C, Spandidos DA. Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 1999;18:4968-73.
14. Ceci JD, Patriotis CP, Tsatsanis C, Makris AM, Kovatch R, Swing DA, et al. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev 1997;11:688-700.
15. Choi HS, Kang BS, Shim JH, Cho YY, Choi BY, Bode AM, et al. Cot, a novel kinase of histone H3, induces cellular transformation through upregulation of c-fos transcriptional activity. FASEB J 2008;22:113-26.
16. Rodriguez C, Lopez P, Pozo M, Duce AM, Lopez-Pelaez M, Fernandez M, et al. COX2 expression and Erk1/Erk2 activity mediate Cot-induced cell migration. Cell Signal 2008;20:1625-31.
17. Hatziapostolou M, Koukos G, Polytarchou C, Kottakis F, Serebrennikova O, Kuliopulos A, et al. Tumor progression locus 2 mediates signalinduced increases in cytoplasmic calcium and cell migration. Sci Signal 2011;4:ra55.
18. Hatziapostolou M, Polytarchou C, Panutsopulos D, Covic L, Tsichlis PN. Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res 2008;68:1851-61.
19. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
20. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-7.
21. Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 2007;28:529-36.
22. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005;208:30-49.
23. Hall JP, Kurdi Y, Hsu S, Cuozzo J, Liu J, Telliez JB, et al. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem 2007;282:33295-304.
24. Tang CH, Chen CF, Chen WM, Fong YC. IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells. J Biol Chem 2011;286:11056-66.
25. Tsou HK, Chen HT, Hung YH, Chang CH, Li TM, Fong YC, et al. HGF and c-Met interaction promotes migration in human chondrosarcoma cells. PLoS ONE 2013;8:e53974.
26. Eiraku M, Takata N, Ishibashi H, Kawada M, Sakakura E, Okuda S, et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 2011;472:51-6.
27. Rodriguez C, Pozo M, Nieto E, Fernandez M, Alemany S. TRAF6 and Src kinase activity regulates Cot activation by IL-1. Cell Signal 2006;18:1376-85.
28. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-26.
29. Park HD, Lee Y, Oh YK, Jung JG, Park YW, Myung K, et al. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene 2011;30:201-11.
30. Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 2005;31:536-45.
31. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
32. Jeong JH, Bhatia A, Toth Z, Oh S, Inn KS, Liao CP, et al. TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS ONE 2011;6:e16205.
33. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008;123:395-400.
34. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569-75.
35. Wang L, Yang B, Yang Q, Qiao S, Wang Y, Sun Y. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. Clin Exp Metastasis 2009;26:1049-54.
36. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307-11.
37. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006;5:56.
38. Wehler TC, Graf C, Biesterfeld S, Brenner W, Schadt J, Gockel I, et al. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease. J Oncol 2008;2008:626340.
39. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-26.
40. Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther 2010;9:409-16.
41. Hamm HE. The many faces of G protein signaling. J Biol Chem 1998;273:669-72.
42. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33:392-406.
43. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000;351 Pt 2:289-305.
44. Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, et al. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2, and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer 2011;47:2353-63.
45. Huynh H, Ong RW, Li PY, Lee SS, Yang S, Chong LW, et al. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma. Anticancer Agents Med Chem 2011;11:560-75.
46. An J, Liu H, Magyar CE, Guo Y, Veena MS, Srivatsan ES, et al. Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma. Cancer Res 2013;73:1374-85.
47. Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, et al. Simvastatin Inhibits Renal Cancer CellGrowth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway. PLoS ONE 2013;8:e62823.
48. Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, et al. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res 2008;68:81-8.